
Thomas Shrader, PhD, CFA, is a Managing Director and Healthcare Analyst at BTIG. He provides coverage of the biotechnology sector, with a focus on large and smidcap companies. Prior to BTIG, Mr. Shrader was the Vice President of Strategy and Communications at Intrexon Corporation. Previously, he was a Biotechnology Research Analyst at Stifel. Earlier in his career, Mr. Shrader was on the Biochemistry Faculty at the Albert Einstein College of Medicine. He earned a BA from The Johns Hopkins University, a PhD from Yale University and was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology.
Coverage Area
Company | Ticker |
---|---|
Precision BioSciences, Inc. | DTIL |
INmune Bio Inc. | INMB |
BioAtla | BCAB |
Gritstone Oncology Inc. | GRTS |
Minerva Neurosciences, Inc. | NERV |
Biogen, Inc. | BIIB |
Denali Therapeutics Inc. | DNLI |
Eidos Therapeutics, Inc. | EIDX |
Esperion Therapeutics, Inc. | ESPR |
Geron Corporation | GERN |
G1 Therapeutics, Inc. | GTHX |
MEI Pharma, Inc. | MEIP |
MacroGenics, Inc. | MGNX |
NeuBase Therapeutics | NBSE |
Arcus Biosciences, Inc. | RCUS |
Seagen Inc. | SGEN |
Synlogic, Inc. | SYBX |
Vaccinex, Inc. | VCNX |
Verona Pharma plc | VRNA |
Voyager Therapeutics, Inc. | VYGR |
Xencor, Inc. | XNCR |
Cue Biopharma, Inc. | CUE |
IMV, Inc. | IMV |
Alector Inc. | ALEC |
Stoke Therapeutics, Inc. | STOK |
Mersana Therapeutics | MRSN |
BridgeBio Pharma, Inc. | BBIO |
Checkmate Pharmaceuticals | CMPI |
Silence Therapeutics | SLN |
Replimune Group, Inc. | REPL |
SQZ Biotechnologies Co | SQZ |